Bereich
Brustzentrum St.Gallen
BZ · Dept. IV
Response-guided neoadjuvant chemotherapy for breast cancer
von Minckwitz G, Mehta K, Zahm D, Untch M, Schneeweiss A, Paepke S, Kümmel S, Kaufmann M, Jackisch C, Huober J, Hilfrich J, Hanusch C, Gerber B, Eiermann W, Eidtmann H, Denkert C, Costa S, Blohmer J, Loibl S. Response-guided neoadjuvant chemotherapy for breast cancer. J Clin Oncol 2013; 31:3623-30.
03.09.2013Response-guided neoadjuvant chemotherapy for breast cancer
03.09.2013J Clin Oncol 2013; 31:3623-30
von Minckwitz Gunter, Mehta Keyur, Zahm Dirk Michael, Untch Michael, Schneeweiss Andreas, Paepke Stefan, Kümmel Sherko, Kaufmann Manfred, Jackisch Christian, Huober Jens, Hilfrich Jörn, Hanusch Claus, Gerber Bernd, Eiermann Wolfgang, Eidtmann Holger, Denkert Carsten, Costa Serban Dan, Blohmer Jens Uwe, Loibl Sibylle
Prospective cost-effectiveness analysis of genomic profiling in breast cancer
Retèl V, Joore M, Drukker C, Bueno-de-Mesquita J, Knauer M, van Tinteren H, Linn S, van Harten W. Prospective cost-effectiveness analysis of genomic profiling in breast cancer. Eur J Cancer 2013; 49:3773-9.
27.08.2013Prospective cost-effectiveness analysis of genomic profiling in breast cancer
27.08.2013Eur J Cancer 2013; 49:3773-9
Retèl V P, Joore M A, Drukker C A, Bueno-de-Mesquita J M, Knauer Michael, van Tinteren H, Linn S C, van Harten W H
German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer
von Minckwitz G, Bauerfeind I, Clemens M, Schmidt M, Noeding S, Forstbauer H, Barinoff J, Belau A, Nekljudova V, Harbeck N, Lück H, Müller V, Kreienberg R, Möbus V, Schneeweiss A, Huober J, Thomssen C, Untch M, Jackisch C, Diel I, Elling D, Conrad B, Loibl S. German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer. J Clin Oncol 2013; 31:3531-9.
26.08.2013German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer
26.08.2013J Clin Oncol 2013; 31:3531-9
von Minckwitz Gunter, Bauerfeind Ingo, Clemens Michael, Schmidt Marcus, Noeding Stefanie, Forstbauer Helmut, Barinoff Jana, Belau Antje, Nekljudova Valentina, Harbeck Nadia, Lück Hans-Joachim, Müller Volkmar, Kreienberg Rolf, Möbus Volker, Schneeweiss Andreas, Huober Jens, Thomssen Christoph, Untch Michael, Jackisch Christian, Diel Ingo J, Elling Dirk, Conrad Bettina, Loibl Sibylle
Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial
Denkert C, Barinoff J, Jackisch C, Prinzler J, Rüdiger T, Erbstösser E, Blohmer J, Budczies J, Mehta K, Fehm T, Huober J, Loibl S, Müller B, Eidtmann H, Schmitt W, Eiermann W, Gerber B, Tesch H, Hilfrich J, von Minckwitz G. Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial. Ann Oncol 2013; 24:2786-93.
22.08.2013Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial
22.08.2013Ann Oncol 2013; 24:2786-93
Denkert C, Barinoff J, Jackisch C, Prinzler J, Rüdiger T, Erbstösser E, Blohmer J U, Budczies J, Mehta K M, Fehm T, Huober Jens, Loibl S, Müller B M, Eidtmann H, Schmitt W D, Eiermann W, Gerber B, Tesch H, Hilfrich J, von Minckwitz G
Optimal sequence of tamoxifen and aromatase inhibitors to prevent bone loss
Zaman K, Thürlimann B, Aebi S. Optimal sequence of tamoxifen and aromatase inhibitors to prevent bone loss. J Clin Oncol 2013; 31:3440-1.
05.08.2013Optimal sequence of tamoxifen and aromatase inhibitors to prevent bone loss
05.08.2013J Clin Oncol 2013; 31:3440-1
Zaman Khalil, Thürlimann Beat, Aebi Stefan
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
Goldhirsch A, Winer E, Coates A, Gelber R, Piccart-Gebhart M, Thürlimann B, Senn H, Panel members. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013; 24:2206-23.
04.08.2013Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
04.08.2013Ann Oncol 2013; 24:2206-23
Goldhirsch A, Winer E P, Coates A S, Gelber R D, Piccart-Gebhart M, Thürlimann Beat, Senn H-J, Panel members
Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial
Moebus V, Untch M, Kreienberg R, Hinke A, Runnebaum I, Nitz U, Kuhn W, Kurbacher C, Thomssen C, du Bois A, Lueck H, Huober J, Schneeweiss A, Jackisch C, AGO Breast Study Group. Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial. J Natl Cancer Inst 2013; 105:1018-26.
16.07.2013Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial
16.07.2013J Natl Cancer Inst 2013; 105:1018-26
Moebus Volker, Untch Michael, Kreienberg Rolf, Hinke Axel, Runnebaum Ingo B, Nitz Ulrike, Kuhn Walther, Kurbacher Christian, Thomssen Christoph, du Bois Andreas, Lueck Hans-Joachim, Huober Jens, Schneeweiss Andreas, Jackisch Christian, AGO Breast Study Group
Expert opinion 2011 on the use of new anti-resorptive agents in the prevention of skeletal-related events in metastatic bone disease.
Anghel R, Bachmann A, Beksac M, Brodowicz T, Finek J, Komadina R, Krzemieniecki K, Láng I, Marencak J, von Moos R, Pecherstorfer M, Rordorf T, Vrbanec D, Zielinski C, ĀăąĆĉČĎ Ā. Expert opinion 2011 on the use of new anti-resorptive agents in the prevention of skeletal-related events in metastatic bone disease. Wien Klin Wochenschr 2013; 125:439-47.
06.07.2013Expert opinion 2011 on the use of new anti-resorptive agents in the prevention of skeletal-related events in metastatic bone disease.
06.07.2013Wien Klin Wochenschr 2013; 125:439-47
Anghel Rodica, Bachmann Alexander, Beksac Meral, Brodowicz Thomas, Finek Jindřich, Komadina Radko, Krzemieniecki Krzysztof, Láng István, Marencak Jozef, von Moos Roger, Pecherstorfer Martin, Rordorf Tamara, Vrbanec Damir, Zielinski Christoph C, ĀăąĆĉČĎ Ā ā Ă ă Ą ą Ć ć Ĉ ĉ Ċ ċ Č č Ď ď Đ đ Ē ē Ĕ ĕ Ė ė Ę ę Ě ě Ĝ ĝ Ğ ğ Ġ ġ Ģ ģ Ĥ ĥ Ħ ħ Ĩ ĩ Ī ī Ĭ ĭ Į į İ ı IJ ij Ĵ ĵ Ķ ķ ĸ Ĺ ĺ Ļ ļ Ľ ľ Ŀ ŀ Ł ł Ń ń Ņ ņ Ň ň ʼn Ŋ ŋ Ō ō Ŏ ŏ Ő ő Œ œ Ŕ ŕ Ŗ ŗ Ř ř Ś ś Ŝ ŝ Ş ş Š š Ţ ţ Ť ť Ŧ ŧ Ũ ũ Ū ū Ŭ ŭ Ů ů Ű ű Ų ų Ŵ ŵ Ŷ ŷ Ÿ Ź ź Ż ż Ž ž ſ
Ki67 measured after neoadjuvant chemotherapy for primary breast cancer
von Minckwitz G, Fehm T, Barinoff J, Rüdiger T, Erbstoesser E, Fasching P, Karn T, Müller V, Jackisch C, Huober J, Hilfrich J, Tesch H, Schmitt W, Loibl S, Müller B, Blohmer J, Sinn B, Eidtmann H, Eiermann W, Gerber B, Denkert C. Ki67 measured after neoadjuvant chemotherapy for primary breast cancer. Clin Cancer Res 2013; 19:4521-31.
27.06.2013Ki67 measured after neoadjuvant chemotherapy for primary breast cancer
27.06.2013Clin Cancer Res 2013; 19:4521-31
von Minckwitz Gunter, Fehm Tanja, Barinoff Jana, Rüdiger Thomas, Erbstoesser Erhard, Fasching Peter A, Karn Thomas, Müller Volkmar, Jackisch Christian, Huober Jens, Hilfrich Jörn, Tesch Hans, Schmitt Wolfgang D, Loibl Sibylle, Müller Berit M, Blohmer Jens U, Sinn Bruno V, Eidtmann Holger, Eiermann Wolfgang, Gerber Bernd, Denkert Carsten
Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer
Jonat W, Bachelot T, Ruhstaller T, Kuss I, Reimann U, Robertson J. Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer. Ann Oncol 2013; 24:2543-8.
20.06.2013Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer
20.06.2013Ann Oncol 2013; 24:2543-8
Jonat W, Bachelot T, Ruhstaller Thomas, Kuss I, Reimann U, Robertson J F R
Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group
Lück H, Schuster T, Wollschläger K, Untch M, Thomssen C, Eidtmann H, Stickeler E, Richter B, Hubalek M, Jackisch C, Stähler A, Beckmann M, Heilmann V, Huober J, Schrader I, Loibl S, du Bois A, von Minckwitz G. Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group. Breast Cancer Res Treat 2013; 139:779-87.
15.06.2013Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group
15.06.2013Breast Cancer Res Treat 2013; 139:779-87
Lück Hans-Joachim, Schuster Tibor, Wollschläger Kerstin, Untch Michael, Thomssen Christoph, Eidtmann Holger, Stickeler Elmar, Richter Barbara, Hubalek Michael, Jackisch Christian, Stähler Ann, Beckmann Matthias, Heilmann Volker, Huober Jens, Schrader Iris, Loibl Sibylle, du Bois Andreas, von Minckwitz Gunter
Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44)
Huober J, Kümmel S, Mau C, Jackisch C, Khandan F, Costa S, Krabisch P, Loibl S, Nekljudova V, Untch M, Höß C, Gerber B, Fasching P, Hanusch C, Rezai M, Eidtmann H, Kittel K, Hilfrich J, Schwedler K, Blohmer J, Tesch H, Minckwitz G. Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44). Eur J Cancer 2013; 49:2284-93.
27.03.2013Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44)
27.03.2013Eur J Cancer 2013; 49:2284-93
Huober Jens, Kümmel Sherko, Mau Christine, Jackisch Christian, Khandan Fariba, Costa Serban Dan, Krabisch Petra, Loibl Sibylle, Nekljudova Valentina, Untch Michael, Höß Cornelia, Gerber Bernd, Fasching Peter A, Hanusch Claus, Rezai Mahdi, Eidtmann Holger, Kittel Kornelia, Hilfrich Jörn, Schwedler Kathrin, Blohmer Jens-Uwe, Tesch Hans, Minckwitz Gunter von
Cross-sectional study of self-reported physical activity, eating habits and use of complementary medicine in breast cancer survivors
Templeton A, Thürlimann B, Baumann M, Mark M, Stoll S, Schwizer M, Dietrich D, Ruhstaller T. Cross-sectional study of self-reported physical activity, eating habits and use of complementary medicine in breast cancer survivors. BMC cancer 2013; 13:153.
25.03.2013Cross-sectional study of self-reported physical activity, eating habits and use of complementary medicine in breast cancer survivors
25.03.2013BMC cancer 2013; 13:153
Templeton Arnoud J, Thürlimann Beat, Baumann Michael, Mark Michael, Stoll Sarah, Schwizer Madeleine, Dietrich Daniel, Ruhstaller Thomas
A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study
Drukker C, van de Vijver M, Rutgers E, Sonke G, van 't Veer L, Knauer M, Roumen R, Wesseling J, van Tinteren H, van Harten W, Retèl V, Bueno-de-Mesquita J, Linn S. A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study. Int J Cancer 2013; 133:929-36.
04.03.2013A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study
04.03.2013Int J Cancer 2013; 133:929-36
Drukker C A, van de Vijver M J, Rutgers E J T, Sonke G S, van 't Veer L J, Knauer Michael, Roumen R M H, Wesseling J, van Tinteren H, van Harten W H, Retèl V P, Bueno-de-Mesquita J M, Linn S C
HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer
Denkert C, von Minckwitz G, Tesch H, Hansmann M, Reinisch M, Engels K, Sinn B, Fasching P, Mehta K, Solbach C, Brase J, Darb-Esfahani S, Kronenwett R, Prinzler J, Loibl S, Huober J, Untch M. HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer. Breast Cancer Res 2013; 15:R11.
07.02.2013HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer
07.02.2013Breast Cancer Res 2013; 15:R11
Denkert Carsten, von Minckwitz Gunter, Tesch Hans, Hansmann Martin-Leo, Reinisch Mattea, Engels Knut, Sinn Bruno V, Fasching Peter A, Mehta Keyur, Solbach Christine, Brase Jan C, Darb-Esfahani Silvia, Kronenwett Ralf, Prinzler Judith, Loibl Sibylle, Huober Jens, Untch Michael
Chemotherapy regimens in early breast cancer: major controversies and future outlook
Jörger M, Thürlimann B. Chemotherapy regimens in early breast cancer: major controversies and future outlook. Expert Rev Anticancer Ther 2013; 13:165-78.
01.02.2013Chemotherapy regimens in early breast cancer: major controversies and future outlook
01.02.2013Expert Rev Anticancer Ther 2013; 13:165-78
Jörger Markus, Thürlimann Beat
The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
Voskens C, Mateus C, Mohr P, Paetzold S, Satzger I, Schadendorf D, Schlaeppi M, Schuler G, Schuler-Thurner B, Trefzer U, Ulrich J, Vaubel J, von Moos R, Weder P, Wilhelm T, Göppner D, Dummer R, Klein C, Keller U, Goldinger S, Loquai C, Robert C, Kaehler K, Berking C, Bergmann T, Bockmeyer C, Eigentler T, Fluck M, Garbe C, Gutzmer R, Grabbe S, Hauschild A, Hein R, Hundorfean G, Justich A, Heinzerling L. The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network. PloS one 2013; 8:e53745.
14.01.2013The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
14.01.2013PloS one 2013; 8:e53745
Voskens Caroline J, Mateus Christine, Mohr Peter, Paetzold Sylvie, Satzger Imke, Schadendorf Dirk, Schlaeppi Marc, Schuler Gerold, Schuler-Thurner Beatrice, Trefzer Uwe, Ulrich Jens, Vaubel Julia, von Moos Roger, Weder Patrik, Wilhelm Tabea, Göppner Daniela, Dummer Reinhard, Klein Christina, Keller Ullrich, Goldinger Simone M, Loquai Carmen, Robert Caroline, Kaehler Katharina C, Berking Carola, Bergmann Tanja, Bockmeyer Clemens L, Eigentler Thomas, Fluck Michael, Garbe Claus, Gutzmer Ralf, Grabbe Stephan, Hauschild Axel, Hein Rüdiger, Hundorfean Gheorghe, Justich Armin, Heinzerling Lucie M
Re-irradiation with and without bevacizumab as salvage therapy for recurrent or progressive high-grade gliomas
Hundsberger T, Brügge D, Putora P, Weder P, Weber J, Plasswilm L. Re-irradiation with and without bevacizumab as salvage therapy for recurrent or progressive high-grade gliomas. J Neurooncol 2013; 112:133-9.
12.01.2013Re-irradiation with and without bevacizumab as salvage therapy for recurrent or progressive high-grade gliomas
12.01.2013J Neurooncol 2013; 112:133-9
Hundsberger Thomas, Brügge Detlef, Putora Paul Martin, Weder Patrik, Weber Johannes, Plasswilm Ludwig
Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer--8-year results of the Breast International Group 02-98 phase III trial
Oakman C, Harvey V, Punzalan L, Dell'orto P, Larsimont D, Steinberg I, Gelber R, Piccart-Gebhart M, Viale G, Gutiérrez J, Thürlimann B, Jakesz R, Francis P, Crown J, Quinaux E, Buyse M, De Azambuja E, Margeli Vila M, Andersson M, Nordenskjöld B, Di Leo A. Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer--8-year results of the Breast International Group 02-98 phase III trial. Ann Oncol 2013; 24:1203-11.
04.01.2013Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer--8-year results of the Breast International Group 02-98 phase III trial
04.01.2013Ann Oncol 2013; 24:1203-11
Oakman C, Harvey V, Punzalan L, Dell'orto P, Larsimont D, Steinberg I, Gelber R D, Piccart-Gebhart M, Viale G, Gutiérrez J, Thürlimann Beat, Jakesz R, Francis P A, Crown J, Quinaux E, Buyse M, De Azambuja E, Margeli Vila M, Andersson M, Nordenskjöld B, Di Leo A
Treatment concepts of oral cancer.
Bredell M, Rordorf T, Studer G. Treatment concepts of oral cancer. SADJ 2012; 67:574-6.
01.11.2012Treatment concepts of oral cancer.
01.11.2012SADJ 2012; 67:574-6
Bredell M G, Rordorf Tamara, Studer G